Table 3. Median percentage availability by World Bank Income Group.
| World Bank Income Group | Therapeutic group | Median % availability | |||||
|---|---|---|---|---|---|---|---|
| Public sector | Private sector | ||||||
| Originator brand | Lowest priced generic | Any product | Originator brand | Lowest priced generic | Any product | ||
| Low-income countries (n = 10) | Cardiovascular | 0% (n = 31) | 42.9% (n = 42) | 45.0%* (n = 34) | 3.3% (n = 30) | 68.6% (n = 41) | 82.9%* (n = 33) |
| Diabetes | 0% (n = 14) | 51.3% (n = 18) | 57.4%* (n = 14) | 12.1% (n = 14) | 65.2% (n = 18) | 69.5%* (n = 14) | |
| COPD | 3.2% (n = 13) | 25.8% (n = 17) | 29.0%* (n = 13) | 20.0% (n = 13) | 44.0% (n = 17) | 83.3%* (n = 13) | |
| CNS | 0% (n = 20) | 44.1% (n = 35) | 35.7%* (n = 28) | 0% (n = 20) | 45.7% (n = 35) | 46.4%* (n = 28) | |
| All medicines | 0% (n = 78) | 40.2% (n = 112) | 43.3%* (n = 89) | 3.2% (n = 77) | 59.1% (n = 111) | 66.7%* (n = 88) | |
| Lower-middle income countries (n = 12) | Cardiovascular | 0% (n = 52) | 74.2% (n = 80) | 74.2% (n = 80) | 6.7% (n = 62) | 85.8% (n = 90) | 88.6% (n = 90) |
| Diabetes | 1.2% (n = 18) | 52.9% (n = 24) | 59.5% (n = 24) | 24.0% (n = 20) | 66.2% (n = 26) | 71.0% (n = 26) | |
| COPD | 4.1% (n = 18) | 51.4% (n = 19) | 51.4% (n = 19) | 18.6% (n = 20) | 59.2% (n = 22) | 63.3% (n = 22) | |
| CNS | 0% (n = 36) | 34.3% (n = 49) | 37.1% (n = 49) | 3.3% (n = 39) | 37.1% (n = 52) | 42.1% (n = 52) | |
| All medicines | 0% (n = 124) | 54.6% (n = 172) | 57.6% (n = 172) | 10.0% (n = 141) | 65.7% (n = 190) | 68.6% (n = 190) | |
| Upper-middle income countries (n = 8) | Cardiovascular | 0% (n = 49) | 58.4% (n = 58) | 60.3% (n = 58) | 55.6% (n = 49) | 86.7% (n = 55) | 93.3% (n = 56) |
| Diabetes | 0% (n = 17) | 61.7% (n = 22) | 64.1% (n = 22) | 60.0% (n = 17) | 71.7% (n = 22) | 89.9% (n = 22) | |
| COPD | 0% (n = 14) | 64.1% (n = 14) | 64.1% (n = 14) | 32.6% (n = 14) | 59.7% (n = 14) | 81.7% (n = 14) | |
| CNS | 0% (n = 37) | 46.7% (n = 42) | 46.7% (n = 42) | 45.8% (n = 37) | 66.7% (n = 41) | 86.7% (n = 41) | |
| All medicines | 0% (n = 117) | 56.7% (n = 136) | 60.2% (n = 136) | 53.3% (n = 117) | 76.7% (n = 132) | 90.0% (n = 133) | |
*Excludes data points for Uganda and Tanzania as originator brands were not surveyed; n = number of data points in the analysis